Cogent Biosciences, Inc. 8K

Cogent Biosciences reported Q2 2026 results, advanced three NDAs for bezuclastinib toward late-2026 FDA decisions, strengthened its commercial infrastructure, and confirmed cash runway into late 2028 despite a higher net loss.

Cogent Biosciences, Inc. reported its second quarter 2026 financial results and recent business developments, highlighting three New Drug Application submissions for its lead drug bezuclastinib in Gastrointestinal Stromal Tumors (GIST), Advanced Systemic Mastocytosis (AdvSM) and Non-Advanced Systemic Mastocytosis, along with FDA acceptance of the GIST NDA with priority review and upcoming PDUFA dates of November 30, 2026 (GIST) and December 30, 2026 (NonAdvSM). The company presented strong pivotal trial data from the Phase 3 PEAK trial in GIST and the APEX trial in AdvSM, initiated an extension cohort in first-line GIST, and completed enrollment in the “avapritinib switch” SUMMIT extension trial. Cogent also advanced its early-stage pipeline (including JAK2 V617F inhibitor CGT1145 and plans to file INDs for KRAS(ON) inhibitor CGT1815 and JAK2 V617F inhibitor CGT1145, and dose escalation for ErbB2 inhibitor CGT4255) and finished building out a national commercial and medical field team in preparation for potential bezuclastinib launches. Financially, the company reported a Q2 2026 net loss of $96.4 million on higher R&D and G&A expenses, a cash and marketable securities balance of $792.3 million as of June 30, 2026 (pro forma $865.9 million including post-quarter ATM proceeds), which it expects will fund operations into late 2028, and it granted inducement equity awards to 59 new employees under its 2020 Inducement Plan.

Filing Facts

CIK

1622229

Ticker

COGT

Form

8K

Source Type

fda

Accession

0001193125-26-341315

Alert Tier

7